Citi analyst Patrick Donnelly lowered the firm’s price target on Quest Diagnostics to $130 from $142 and keeps a Neutral rating on the shares. The company’s Q3 came in lighter than anticipated leading management to decrease the fiscal 2023 target once again to slightly below 16.5%, the analyst tells investors in a research note. The firm cites the softer margin outlook for the target drop.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DGX:
- Quest Diagnostics narrows FY23 adjusted EPS view to $8.65-$8.75 from $8.50-$8.90
- Quest Diagnostics Reports Third Quarter 2023 Financial Results; Updates Guidance for Full Year 2023
- Quest Diagnostics reports Q3 adjusted EPS $2.22, consensus $2.19
- Notable companies reporting before tomorrow’s open
- Quest Diagnostics (DGX) Q3 Earnings Cheat Sheet